Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

[1] Hanahan D(2000)The hallmarks of cancer Cell 100 57-70

[2] Weinberg RA(2002)Measuring the clinical response. What does it mean? Eur J Cancer 38 1817-1823

[3] Therasse P(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216

[4] Therasse P(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247

[5] Arbuck SG(2004)Histological quantitation of tumour angiogenesis APMIS 112 413-430

[6] Eisenhauer EA(2007)The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients Eur Radiol 17 1700-1713

[7] Wanders J(2004)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145-147

[8] Kaplan RS(2004)A phase I surrogate endpoint study of SU6668 in patients with solid tumors Invest New Drugs 22 459-466

[9] Rubinstein L(2003)Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 223-231

[10] Verweij J(2007)Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging Am J Clin Oncol 30 315-318

[1] Hanahan D(2000)The hallmarks of cancer Cell 100 57-70

[2] Weinberg RA(2002)Measuring the clinical response. What does it mean? Eur J Cancer 38 1817-1823

[3] Therasse P(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216

[4] Therasse P(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247

[5] Arbuck SG(2004)Histological quantitation of tumour angiogenesis APMIS 112 413-430

[6] Eisenhauer EA(2007)The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients Eur Radiol 17 1700-1713

[7] Wanders J(2004)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145-147

[8] Kaplan RS(2004)A phase I surrogate endpoint study of SU6668 in patients with solid tumors Invest New Drugs 22 459-466

[9] Rubinstein L(2003)Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 223-231

[10] Verweij J(2007)Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging Am J Clin Oncol 30 315-318